Artiva Biotherapeutics Inc (ARTV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.13-2.13%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ARTV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Company also announced that it is implementing a reduction in workforce and evaluating strategic alternatives to maximize stockholder value that may include a merger, business combination, sale o…
Stated in a supplied disclosure. Management reported: “As of September 30, 2026, Artiva had approximately $319.1 million in cash, cash equivalents and investments (preliminary and unaudited).” “In connection with the discontinuation of AlloNK development and to preserve capital while evaluating strategic alternatives, Artiva is reducing its workforce by approximately 94%.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
(Nasdaq: ARTV) (Artiva or the Company), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune dise…
Stated in a supplied disclosure. Management reported: “No additional patients will be dosed in any ongoing AlloNK clinical study and the planned Phase 3 pivotal trial will not be initiated.” “The Company will work closely with the FDA, investigators and institutional review boards to ensure an appropriate and orderly close-out of its clinical development program, including continued safety monitoring and reporting as required.”
In connection with the discontinuation of AlloNK development and to preserve capital while evaluating strategic alternatives, Artiva is reducing its workforce by approximately 94%.
Stated in a supplied disclosure. Management reported: “In connection with the discontinuation of AlloNK development and to preserve capital while evaluating strategic alternatives, Artiva is reducing its workforce by approximately 94%.” “As of September 30, 2026, Artiva had approximately $319.1 million in cash, cash equivalents and investments (preliminary and unaudited).”
Start a Phase 3 randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients in H2 2026.
Present clinical, safety, and translational data for AlloNK at EULAR 2026 and share initial clinical response data in refractory RA and other autoimmune diseases.
Over the trailing year it converted 1.43x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.